Edgewise Therapeutics (EWTX) to Release Earnings on Thursday

Edgewise Therapeutics (NASDAQ:EWTX) will likely be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 9:30 AM ET.

Edgewise Therapeutics (NASDAQ:EWTX) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.08. On average, analysts expect Edgewise Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Edgewise Therapeutics Stock Down 3.6%

Shares of NASDAQ EWTX opened at $17.33 on Wednesday. The firm’s 50-day moving average price is $15.35 and its two-hundred day moving average price is $14.66. Edgewise Therapeutics has a 52-week low of $10.60 and a 52-week high of $38.12. The stock has a market capitalization of $1.83 billion, a P/E ratio of -11.18 and a beta of 0.30.

Insiders Place Their Bets

In other news, CEO Kevin Koch sold 7,972 shares of the stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $13.39, for a total value of $106,745.08. Following the completion of the transaction, the chief executive officer owned 30,615 shares of the company’s stock, valued at approximately $409,934.85. This represents a 20.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Alan J. Russell sold 100,000 shares of the firm’s stock in a transaction on Tuesday, August 26th. The shares were sold at an average price of $14.60, for a total value of $1,460,000.00. Following the transaction, the insider directly owned 23,400 shares in the company, valued at $341,640. This trade represents a 81.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 116,267 shares of company stock worth $1,677,815. Insiders own 23.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System increased its stake in shares of Edgewise Therapeutics by 2.4% during the second quarter. California State Teachers Retirement System now owns 36,878 shares of the company’s stock valued at $483,000 after acquiring an additional 850 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Edgewise Therapeutics by 14.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,148 shares of the company’s stock valued at $120,000 after purchasing an additional 1,188 shares during the period. Legal & General Group Plc raised its stake in shares of Edgewise Therapeutics by 3.9% in the 2nd quarter. Legal & General Group Plc now owns 52,307 shares of the company’s stock worth $686,000 after buying an additional 1,959 shares in the last quarter. Jones Financial Companies Lllp acquired a new stake in shares of Edgewise Therapeutics in the first quarter valued at $47,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Edgewise Therapeutics by 6.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,776 shares of the company’s stock valued at $963,000 after buying an additional 2,463 shares during the period.

Analyst Ratings Changes

Several brokerages recently issued reports on EWTX. The Goldman Sachs Group started coverage on Edgewise Therapeutics in a report on Thursday, September 25th. They issued a “neutral” rating and a $20.00 price target on the stock. Raymond James Financial began coverage on Edgewise Therapeutics in a research report on Wednesday, July 30th. They issued a “strong-buy” rating and a $46.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Edgewise Therapeutics in a research note on Wednesday, October 8th. Royal Bank Of Canada boosted their price target on shares of Edgewise Therapeutics from $48.00 to $49.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Edgewise Therapeutics from $40.00 to $30.00 and set an “overweight” rating for the company in a research report on Tuesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $38.83.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.